247 related articles for article (PubMed ID: 35924672)
1. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Ruiz-Ortiz M; Muñiz J; Roldán-Rabadán I; Otero D; López-Gálvez R; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
Expert Opin Pharmacother; 2022 Aug; 23(12):1457-1465. PubMed ID: 35924672
[TBL] [Abstract][Full Text] [Related]
2. Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.
Abdrakhmanov A; Shaimerdinova A; Suleimen Z; Abildinova S; Albayev R; Tuyakova G; Rib E; Beysenbayeva A; Kabduyeva G; Bekbossynova M
Ther Adv Cardiovasc Dis; 2024; 18():17539447241249886. PubMed ID: 38801157
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Lorenzoni V; Pirri S; Turchetti G
Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
[TBL] [Abstract][Full Text] [Related]
6. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.
Deitelzweig S; Bergrath E; di Fusco M; Kang A; Savone M; Cappelleri JC; Russ C; Betts M; Cichewicz A; Schaible K; Tarpey J; Fahrbach K
Future Cardiol; 2022 May; 18(5):393-405. PubMed ID: 35360925
[TBL] [Abstract][Full Text] [Related]
7. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
8. [Neurological perspective in the choice of direct oral anticoagulants for prevention of stroke in atrial fibrillation].
Ameriso SF; Pujol Lereis VA
Medicina (B Aires); 2023; 83(2):273-277. PubMed ID: 37094196
[TBL] [Abstract][Full Text] [Related]
9. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
11. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
13. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB
Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.
Sharma M; Cornelius VR; Patel JP; Davies JG; Molokhia M
Circulation; 2015 Jul; 132(3):194-204. PubMed ID: 25995317
[TBL] [Abstract][Full Text] [Related]
15. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
Trujillo TC; Dobesh PP; Crossley GH; Finks SW
Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Marston XL; Wang R; Yeh YC; Zimmermann L; Ye X; Gao X; Brüggenjürgen B; Unverdorben M
Int J Cardiol; 2022 Jan; 346():93-99. PubMed ID: 34780886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]